Abstract
Several relatively strong risk factors for breast cancer that affect large proportions of the general population have been known for some time. Nevertheless, few effective preventive interventions have been developed, probably because most of the recognized risk factors relate to reproductive factors that are, in a practical sense, nonmodifiable. The response to this situation has been enthusiasm for identifying the underlying biologic mechanisms associated with these recognized risk factors, with the expectation that these mechanisms could be exploited directly rather than altering the risk factors responsible for them. An example is the solid evidence from both laboratory and population studies of the growth-promoting action of estrogen relatively late in carcinogenesis, which led to the studies of tamoxifen as a chemopreventive agent. Risk–benefit considerations have limited the applicability of this regimen to those women at the highest risk of breast cancer, but the success among this group has created considerable enthusiasm for the development of selective estrogen receptor modulators with much lower toxic effects.

This publication has 6 references indexed in Scilit: